Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficac ....Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficacious and stable formulations of bacteriophages for easy delivery by inhalation as aerosols with a long shelf-life, making them a commercially viable product. The expected research outcome can lead to an economic and efficient technology to produce phage powders for novel treatment strategies of infections by inhalation.Read moreRead less
Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficac ....Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficacious and stable formulations of bacteriophages for easy delivery by inhalation as aerosols with a long shelf-life, making them a commercially viable product. The expected research outcome can lead to an economic and efficient technology to produce phage powders for novel treatment strategies of infections by inhalation.Read moreRead less
Novel nano-composite particles for controlled-release drugs via inhalation. This project will explore a novel nano-medicine technology using nanocrystals in liposomes to design new composite particles to enable optimal release of antibiotics delivered by inhalation. Respiratory infection caused by multidrug-resistant bacteria is a major health problem worldwide. Controlled-release products using liposomes simplify dose regimen and enhance bacterial killing. Currently, aerosolised liposomes are l ....Novel nano-composite particles for controlled-release drugs via inhalation. This project will explore a novel nano-medicine technology using nanocrystals in liposomes to design new composite particles to enable optimal release of antibiotics delivered by inhalation. Respiratory infection caused by multidrug-resistant bacteria is a major health problem worldwide. Controlled-release products using liposomes simplify dose regimen and enhance bacterial killing. Currently, aerosolised liposomes are limited to liquid forms with limited control over release and stability. The project will provide new technology on manufacturing composite powders of antibiotics that may ultimately lead to the development of effective new treatments against drug-resistant bacteria.Read moreRead less
Novel nano-composite particles for controlled-release drugs via inhalation. This project will explore a novel nano-medicine technology using nanocrystals in liposomes to design new composite particles to enable optimal release of antibiotics delivered by inhalation. Respiratory infection caused by multidrug-resistant bacteria is a major health problem worldwide. Controlled-release products using liposomes simplify dose regimen and enhance bacterial killing. Currently, aerosolised liposomes are l ....Novel nano-composite particles for controlled-release drugs via inhalation. This project will explore a novel nano-medicine technology using nanocrystals in liposomes to design new composite particles to enable optimal release of antibiotics delivered by inhalation. Respiratory infection caused by multidrug-resistant bacteria is a major health problem worldwide. Controlled-release products using liposomes simplify dose regimen and enhance bacterial killing. Currently, aerosolised liposomes are limited to liquid forms with limited control over release and stability. The project will provide new technology on manufacturing composite powders of antibiotics that may ultimately lead to the development of effective new treatments against drug-resistant bacteria.Read moreRead less
Fundamentals and applications of continuous-flow microprocessing systems based on supercritical fluids and gas expanded liquids. Microchemical systems have considerable potential in the area of chemical discovery and development. Practical application of these systems requires fundamental understanding and strategies for conversion to appropriate scale. The aim of this project is to overcome such challenges in the development of microstructured continuous-flow technology.
Production of nano-composite particles for inhalational delivery of combination drugs. The project seeks to create a new particle engineering process for pharmaceuticals. The successful outcome will i) enhance substantially the competitiveness of Australia’s research in functional nanomaterials and advanced biomaterials, and ii) benefit the Australian pharmaceutical industry in developing proprietary pharmaceutical formulations.